Search details
1.
Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.
Immunity
; 34(2): 269-80, 2011 Feb 25.
Article
in English
| MEDLINE | ID: mdl-21315623
2.
Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Malar J
; 10: 359, 2011 Dec 13.
Article
in English
| MEDLINE | ID: mdl-22166048
3.
Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.
Malar J
; 8: 314, 2009 Dec 30.
Article
in English
| MEDLINE | ID: mdl-20042100
4.
Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
Clin Immunol
; 127(2): 188-97, 2008 May.
Article
in English
| MEDLINE | ID: mdl-18337175
5.
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine.
Cancer Lett
; 263(2): 291-301, 2008 May 18.
Article
in English
| MEDLINE | ID: mdl-18291576
6.
Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation.
Chem Biol
; 14(5): 577-87, 2007 May.
Article
in English
| MEDLINE | ID: mdl-17524988
7.
Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology.
Hum Vaccin
; 4(2): 106-14, 2008.
Article
in English
| MEDLINE | ID: mdl-18382133
8.
Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
Antiviral Res
; 76(1): 75-85, 2007 Oct.
Article
in English
| MEDLINE | ID: mdl-17617476
9.
Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites.
Peptides
; 28(10): 2051-60, 2007 Oct.
Article
in English
| MEDLINE | ID: mdl-17875342
10.
Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.
Wien Klin Wochenschr
; 118(19-20 Suppl 3): 50-7, 2006.
Article
in English
| MEDLINE | ID: mdl-17131241
11.
Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.
J Mol Neurosci
; 27(2): 157-66, 2005.
Article
in English
| MEDLINE | ID: mdl-16186626
12.
Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine.
Expert Rev Vaccines
; 2(2): 295-304, 2003 Apr.
Article
in English
| MEDLINE | ID: mdl-12899579
13.
A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models.
Vaccine
; 30(30): 4490-8, 2012 Jun 22.
Article
in English
| MEDLINE | ID: mdl-22561143
14.
Influenza virosomes as a vaccine adjuvant and carrier system.
Expert Rev Vaccines
; 10(4): 437-46, 2011 Apr.
Article
in English
| MEDLINE | ID: mdl-21506642
15.
Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.
PLoS One
; 6(7): e22273, 2011.
Article
in English
| MEDLINE | ID: mdl-21799810
16.
A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate.
Angew Chem Int Ed Engl
; 42(21): 2368-71, 2003 May 30.
Article
in English
| MEDLINE | ID: mdl-12783498
17.
Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells.
Vaccine
; 27(46): 6415-9, 2009 Oct 30.
Article
in English
| MEDLINE | ID: mdl-19559121
18.
Development of influenza virosome-based synthetic malaria vaccines.
Expert Opin Drug Discov
; 3(4): 415-23, 2008 Apr.
Article
in English
| MEDLINE | ID: mdl-23489097
19.
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
PLoS One
; 3(1): e1493, 2008 Jan 30.
Article
in English
| MEDLINE | ID: mdl-18231580
20.
Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells.
Vaccine
; 25(19): 3913-21, 2007 May 10.
Article
in English
| MEDLINE | ID: mdl-17336432